Evaluation of T-cell immunoglobulin mucin 3 (TIM3) as ahighly sensitive minimal residual disease (MRD) monitoring strategy to predict relapse after Bone Marrow Transplant

Mohamed Saad Mohamed Ahmed El safty;

Abstract


Disease recurrence is a devastating event after allogeneic hematopoietic stem cell transplantation as treatment for acute leukemia. Median time to relapse is approximately 4 months and the majority of relapses occur within 2 years after transplant. The prognosis is usually poor. Overall 5-year survival of all patients relapsing post-transplant for acute leukemia
Evaluation of TIM-3 level is highly monitoring strategy used as minimal residual disease to predict relapse post bone marrow transplant.
TIM-3 level post BMT has significant relation with over-all survival and disease free survival in cases of acute leukemia post allograft


Other data

Title Evaluation of T-cell immunoglobulin mucin 3 (TIM3) as ahighly sensitive minimal residual disease (MRD) monitoring strategy to predict relapse after Bone Marrow Transplant
Other Titles دلالة تقييم الخلية المناعية المخاطية تي3 واستخدامها كمقياس للحد الادني المتبقي للمرض كمؤشر لحدوث انتكاسة مابعد عملية زرع النخاع العظمي
Authors Mohamed Saad Mohamed Ahmed El safty
Issue Date 2020

Attached Files

File SizeFormat
BB7199.pdf1.57 MBAdobe PDFView/Open
Recommend this item

Similar Items from Core Recommender Database

Google ScholarTM

Check



Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.